Sanofi $SNY Shares Purchased by Neuberger Berman Group LLC

Key Points

• Neuberger Berman Group LLC significantly increased its position in Sanofi by 85.7% in Q1, acquiring a total of 37,216 shares valued at approximately $2.06 million.
• Multiple hedge funds have adjusted their stakes in Sanofi, with Regal Partners Ltd raising its stake by 5.4% and Russell Investments Group Ltd. increasing its stake by 18.1% during the same period.
• Analyst ratings for Sanofi have been largely positive, with the stock receiving an average rating of "Buy" and several upgrades from various financial institutions in recent months.

Neuberger Berman Group LLC boosted its holdings in Sanofi (NASDAQ:SNY - Free Report) by 85.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,216 shares of the company's stock after purchasing an additional 17,175 shares during the period. Neuberger Berman Group LLC's holdings in Sanofi were worth $2,064,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Accent Capital Management LLC bought a new position in Sanofi during the 1st quarter valued at approximately $29,000. Eastern Bank boosted its stake in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the last quarter. Bessemer Group Inc. lifted its position in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares in the last quarter. Finally, Brentview Investment Management LLC purchased a new position in Sanofi during the first quarter valued at $42,000. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SNY shares. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $62.00.

Sanofi Stock Up 0.9%

Shares of SNY traded up $0.4350 during midday trading on Tuesday, hitting $50.2750. 1,017,365 shares of the company's stock traded hands, compared to its average volume of 2,575,839. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The firm's fifty day moving average is $48.57 and its 200-day moving average is $51.78. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $123.45 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the business earned $1.73 EPS. As a group, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.